Follicum develops new direct-to-scalp formulation

The topical treatment for hair loss boasts a 'commercial' formulation.

In Follicum's ongoing Phase IIa study, patients with hair loss are being treated with intradermal injections in the scalp. In parallel with this clinical trial, the company has been carrying out long-term development work which has now resulted in a new formulation for application directly to the scalp. The new product has been shown to effectively deliver the active substance into the skin and the hair follicles. The chosen formulation has also been shown to be stable in long-term storage. The product will now be optimized for manufacturing on a larger scale for use in future Phase II trials.

CEO Jan Alenfall comments: "This breakthrough is an important milestone for Follicum. We are very pleased to have developed and chosen a formulation that has the characteristics desired for a commercial product in this segment. Our extensive experience in developing peptide drugs has been a great help in developing a stable formulation delivering FOL-005 to the hair follicle. We look forward to starting a follow-up Phase II study to confirm the effect on hair growth with a formulation that the patients can easily administer on their own."